Summary
Definição
História e exame físico
Principais fatores diagnósticos
- upper extremity weakness
- stiffness, with poor coordination and balance
- spastic, unsteady gait
- painful muscle spasms
- difficulties arising from chairs and climbing stairs
- foot drop
- stiffness and decreased balance with impact on gait
- head drop
- progressive difficulties maintaining erect posture, with stooping
- muscle atrophy
- increased lumbar lordosis and tendency for abdominal protuberance
- hyperreflexia
- dyspnea
- coughing and choking on liquids (including secretions) and eventually on food
- strained, slow speech
- slurred, nasal, and, at times, dysphonic speech
- hypophonic speech
Outros fatores diagnósticos
- propensity for falls
- sialorrhea and drooling
- inappropriate bursts of crying or laughing
- cognitive impairment
- features of frontotemporal dementia
Fatores de risco
- genetic predisposition or family history
- age >40 years
- military service
- professional athletic activity
- cigarette smoking
- agricultural chemical exposure
- lead exposure
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- clinical diagnosis
Investigações a serem consideradas
- electromyography (EMG) and nerve conduction studies
- repetitive nerve stimulation
- MRI brain and spine
- anti-GM1 antibodies
- voltage-gated calcium-channel antibodies
- acetylcholine receptor (AChR) and muscle-specific tyrosine kinase (MuSK) antibodies
- vitamin B₁₂
- creatine kinase
- lumbar puncture
- HIV test
- genetic testing
Algoritmo de tratamento
all patients
Colaboradores
Autores
Christen Shoesmith, MD, FRCPC
Associate Professor of Neurology
Clinical Neurological Sciences
London Health Sciences Centre
London
Ontario
Canada
Declarações
CS has received honoraria from Mitsubishi Tanabe Pharma Canada for participating in scientific medical advisory boards and for presenting at ALS CME events. She has also received stipends for consultancy work for Biogen. She is the chair of the CALS (Canadian ALS Research Network) and in that capacity sits on the scientific medical advisory board for ALS Canada. She is the site PI for several multicenter clinical trials, including trials sponsored by Mitsubishi Tanabe, AL-S Pharma, Sanofi, Calico, and Cytokintetics. CS is an author of references cited in this topic.
Agradecimentos
Dr Christen Shoesmith would like to gratefully acknowledge Professor Christopher J. McDermott, Dr Laura Simionescu, and Dr Jeremy Shefner, previous contributors to this topic.
Declarações
CJM received fees for membership of data monitoring committees from Orion Pharma and Orphazyme. LS and JS declare that they have no competing interests.
Revisores
William S. David, MD, PhD
Associate Professor of Neurology
Harvard Medical School
Boston
MA
Declarações
WSD declares that he has no competing interests.
Leo McCluskey, MD MBE
Associate Professor of Neurology
University of Pennsylvania
Philadelphia
PA
Declarações
LM declares that he has no competing interests.
Martin R. Turner, MA, MBBS, PhD, MRCP
MRC/MNDA Lady Edith Wolfson Clinician Scientist & Honorary Consultant Neurologist
Oxford University Department of Clinical Neurology
John Radcliffe Hospital
Oxford
UK
Declarações
MRT is a co-author of "Motor Neuron Disease – A Practical Manual" (Oxford University Press, 2010), which is a summary of his own understanding and practice, and which strongly influenced the recommendations for revision of the current article. He receives a proportion of royalties derived from sales of this book.
Diagnósticos diferenciais
- Cervical spondylosis with myelopathy and radiculopathy
- Multifocal motor neuropathy
- Inclusion body myositis
Mais Diagnósticos diferenciaisDiretrizes
- Evidence-based consensus guidelines for ALS genetic testing and counseling
- Respiratory management of patients with neuromuscular weakness
Mais DiretrizesConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal